BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is considered one of the best stocks to buy under $20.
On October 1, BioCryst Pharmaceuticals announced the successful completion of the previously announced sale of its European ORLADEYO (berotralstat) business to Neopharmed Gentili.
The transaction is valued at $250 million upfront, subject to customary purchase price adjustments, with the potential for additional payments. This strategic move positions BioCryst to focus on its core operations while benefiting from the value generated by the sale.
https://ca.finance.yahoo.com/news/biocryst-sells-european-orladeyo-business-205450678.html
